CAMBRIDGE, Mass. — ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming June 2026 conferences, and will be available for one-on-one meetings.
Conference details below:
Jefferies Global Healthcare Conference, June 2-4, 2026
Location: New York, NY
Presentation: Thursday, June 4, 2026, from 11:40 a.m. to 12:10 p.m. ET
Webcast link: Click here.
Virtual Alzheimer’s R&D Day, organized by Wolfe Research, June 4, 2026
Presentation: Thursday, June 4, 2026, from 8:30 a.m. to 9:00 a.m. ET (invitation-only)
The event will feature leading companies and key opinion leaders in Alzheimer’s disease research, discussing the current treatment landscape, development of disease modifying therapies and symptom management.
Oppenheimer CNS Summit, June 10, 2026
Location: Miami, FL
One-on-one meetings only
H.C. Wainwright Neuro Perspectives Expert Summit, June 15-16, 2026
Location: New York, NY
Presentation: Monday, June 15, 2026
Webcast link: Click here
BIO International Convention, June 22-25, 2026
Location: San Diego, CA
One-on-one meetings only
During these conferences, Neil Warma, CEO of ProMIS Neurosciences, will discuss the Company’s EpiSelect™ platform and differentiated approach to developing therapeutics for neurodegenerative diseases driven by toxic misfolded proteins, including its lead Alzheimer’s disease (AD) candidate, PMN310.
PMN310 is designed to selectively target toxic amyloid-beta oligomers believed to drive AD pathology while avoiding plaque binding, an approach intended to potentially reduce off-target effects associated with plaque-directed therapies.
ProMIS expects to report blinded 6-month interim data from its fully enrolled PRECISE-AD Phase 1b trial in patients with early AD in early Q3 2026, with 12-month topline data anticipated in early 2027.
Webcast replays of the presentations will be available in the Investors section of the ProMIS Neurosciences website at https://www.promisneurosciences.com/ under “News & Events”.
About ProMIS Neurosciences Inc.
ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies and vaccines selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The Company’s proprietary target discovery engine, EpiSelect™, has been shown to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative and other misfolded protein diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson’s Disease (PD). ProMIS has offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (CAN).
Investor Relations Contact:
Carie Pierce VP, Investor Relations & External Affairs
IR@promisneurosciences.com
Source: ProMIS Neurosciences Inc.
Facebook Linkedin Spotify Twitter
©2026 ProMIS Neurosciences, Inc. All Rights Reserved.
Disclaimer Sitemap Cookie Policy Privacy Policy
